<DOC>
	<DOC>NCT02960763</DOC>
	<brief_summary>The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression.</brief_summary>
	<brief_title>Optimizing Outcomes of Treatment-Resistant Depression in Older Adults</brief_title>
	<detailed_description>Older adult participants with treatment-resistant depression will be randomly assigned to a Step 1 medication strategy. - Adding aripiprazole to current antidepressant medication - Adding bupropion to current antidepressant medication - Replacing current antidepressant medication with bupropion If depression is not relieved at the end of 10 weeks, participants will be randomly assigned to a Step 2 medication strategy: - Adding lithium to current antidepressant medication - Replacing current antidepressant medication with nortriptyline All medication strategies will be offered in collaboration with participants' own physicians with the the research team providing support and guidance. If depression has been relieved after Step 1 or 2, participants will enter the Continuation Phase to assess long term follow-up outcomes for 12 months.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Men and women aged 60 and older Current Major Depressive Disorder (MDD) Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length (at least 12 weeks) Patient Health Questionnaire9 (PHQ9) score of 6 or higher Inability to provide informed consent Dementia Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms High risk for suicide and unable to be managed safely in the clinical trial Contraindication to proposed study medications, as determined by study physician including history of intolerance or nonresponse to proposed medications. Noncorrectable, clinically significant sensory impairment interfering with participation Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management. Moderate to severe substance or alcohol use disorder</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Comparative Effectiveness Research</keyword>
	<keyword>Pragmatic Clinical Trials</keyword>
	<keyword>Patient-Centered Outcomes Research</keyword>
</DOC>